Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Jiamsakul, Awachana ^a   Kantor, Rami ^b   Li, Patrick C K ^c   Sirivichayakul, Sunee ^d   Sirisanthana, Thira ^e   Kantipong, Pacharee ^f   Lee, Christopher K C ^g   Kamarulzaman, Adeeba ^h   Ratanasuwan, Winai ⁱ   Ditangco, Rossana ^j   Singtoroj, Thida ^k   Sungkanuparph, Somnuek ^l  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BROWN UNIVERSITY   (United States)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e CHIANG MAI UNIVERSITY   (Thailand)

^f Chiangrai Prachanukroh Regional Hospital   (Thailand)

^g HOSPITAL SUNGAI BULOH   (Malaysia)

^h UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

^j RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^k TREAT Asia   (Thailand)

^l MAHIDOL UNIVERSITY   (Thailand)

more..

Author keywords

Algorithm; Asia; HIV; Interpretation; Resistance

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; ASIA; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE;

ANTI-HIV AGENTS; ASIA; COHORT STUDIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PHENOTYPE;

EID: 84867681935     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-582     Document Type: Article

References (35)

1. Global HIV/AIDS response, epidemic update and health sector progress towards universal access: progress report 2011 WHO Library Cataloguing-in- Publication Data. 2011
2. The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. Liao L, Xing H, Shang H, Li J, Zhong P, Kang L, Cheng H, Si X, Jiang S, Li X, et al. J Acquir Immune Defic Syndr 2010 53 Suppl 1 10 14 20104099
3. Prevalence of HIV type 1 antiretroviral drug resistance mutations in Vietnam: a multicenter study. Dean J, Ta Thi TH, Dunford L, Carr MJ, Nguyen LT, Coughlan S, Connell J, Nguyen HT, Hall WW, Nguyen Thi LA, AIDS Res Hum Retroviruses 2011 27 7 797 801 10.1089/aid.2011.0013 21366425
4. HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. Hamers RL, Siwale M, Wallis CL, Labib M, van Hasselt R, Stevens WS, Schuurman R, Wensing AM, Van Vugt M, Rinke de Wit TF, J Acquir Immune Defic Syndr 2010 55 1 95 101 10.1097/QAI.0b013e3181e544e0 20585262
5. Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand. Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, Thongprapai H, Kittihanukul C, Kamudamas A, Tungsathapornpong A, Mundy LM, HIV Med 2008 9 5 322 325 10.1111/j.1468-1293.2008.00562.x 18400079 (Pubitemid 351522665)
6. HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Sungkanuparph S, Oyomopito R, Sirivichayakul S, Sirisanthana T, Li PC, Kantipong P, Lee CK, Kamarulzaman A, Messerschmidt L, Law MG, et al. Clin Infect Dis 2011 52 8 1053 1057 10.1093/cid/cir107 21460324
7. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. Holguin A, Ramirez de Arellano E, Rivas P, Soriano V, AIDS Rev 2006 8 2 98 107 16848277 (Pubitemid 44043558)
8. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Kantor R, Curr Opin Infect Dis 2006 19 6 594 606 10.1097/QCO.0b013e3280109122 17075337 (Pubitemid 44665467)
9. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, et al. PLoS Med 2005 2 4 112 10.1371/journal.pmed.0020112 15839752 (Pubitemid 40721078)
10. Web resources for HIV type 1 genotypic-resistance test interpretation. Liu TF, Shafer RW, Clin Infect Dis 2006 42 11 1608 1618 10.1086/503914 16652319
11. Rationale and uses of a public HIV drug-resistance database. Shafer RW, J Infect Dis 2006 194 Suppl 1 51 58 16921473
12. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P, J Virol Methods 2007 145 1 47 55 10.1016/j.jviromet.2007.05.009 17574687 (Pubitemid 47247892)
13. Development and performance of conventional HIV-1 phenotyping (Antivirogram(R)) and genotype-based calculated phenotyping assay (virco(R)TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance. Pattery T, Verlinden Y, De Wolf H, Nauwelaers D, Van Baelen K, Van Houtte M, Mc Kenna P, Villacian J, Intervirology 2012 55 2 138 146 10.1159/000332013 22286884
14. A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences. Steegen K, Bronze M, Van Craenenbroeck E, Winters B, Van der Borght K, Wallis CL, Stevens W, de Wit TF R, Stuyver LJ, AIDS Res Ther 2010 7 38 10.1186/1742-6405-7-38 20950432
15. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain. Mũoz M, Carmona R, Pérez-Alvarez L, Cilla G, Suarez MD, Delgado E, Contreras G, Corral J, de Goicoetxea MJL, Medrano L, et al. Journal of Clinical Virology 2005 33 3 224 229 10.1016/j.jcv.2004.06.014 15911444 (Pubitemid 40720442)
16. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Sturmer M, Doerr HW, Staszewski S, Preiser W, Antivir Ther 2003 8 3 239 244 12924541 (Pubitemid 36960898)
17. Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains. Puchhammer-Stockl E, Steininger C, Geringer E, Heinz FX, HIV Med 2002 3 3 200 206 10.1046/j.1468-1293.2002.00116.x 12139659
18. Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype. Zazzi M, Romano L, Venturi G, Shafer RW, Reid C, Dal Bello F, Parolin C, Palu G, Valensin PE, J Antimicrob Chemother 2004 53 2 356 360 10.1093/jac/dkh021 14688053 (Pubitemid 38239973)
19. Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. Liu L, May S, Richman DD, Hecht FM, Markowitz M, Daar ES, Routy JP, Margolick JB, Collier AC, Woelk CH, et al. AIDS 2008 22 7 835 839 10.1097/QAD.0b013e3282f5ff71 18427201 (Pubitemid 351563832)
20. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. Vergne L, Snoeck J, Aghokeng A, Maes B, Valea D, Delaporte E, Vandamme AM, Peeters M, Van Laethem K, FEMS Immunol Med Microbiol 2006 46 1 53 62 10.1111/j.1574-695X.2005.00011.x 16420597
21. A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand. Poonpiriya V, Sungkanuparph S, Leechanachai P, Pasomsub E, Watitpun C, Chunhakan S, Chantratita W, J Virol Methods 2008 151 1 79 86 10.1016/j.jviromet.2008.03.017 18462814
22. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Snoeck J, Kantor R, Shafer RW, Van Laethem K, Deforche K, Carvalho AP, Wynhoven B, Soares MA, Cane P, Clarke J, et al. Antimicrob Agents Chemother 2006 50 2 694 701 10.1128/AAC.50.2.694-701.2006 16436728 (Pubitemid 43190984)
23. HIV-1 non-B subtypes: High transmitted NNRTI-resistance in Spain and impaired genotypic resistance interpretation due to variability. Yebra G, de Mulder M, del Romero J, Rodriguez C, Holguin A, Antiviral Res 2010 85 2 409 417 10.1016/j.antiviral.2009.11.010 20004217
24. Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance - HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Hamers RL, Oyomopito R, Kityo C, Phanuphak P, Siwale M, Sungkanuparph S, Conradie F, Kumarasamy N, Botes ME, Sirisanthana T, et al. Int J Epidemiol 2011
25. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, Chen YM, Oka S, DeLong A, Sayer D, et al. J Virol Methods 2009 159 2 185 193 10.1016/j.jviromet.2009. 03.016 19490972
26. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. Winters B, Van Craenenbroeck E, Van der Borght K, Lecocq P, Villacian J, Bacheler L, J Virol Methods 2009 162 1-2 101 108 19654022
27. Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. Winters B, Montaner J, Harrigan PR, Gazzard B, Pozniak A, Miller MD, Emery S, van Leth F, Robinson P, Baxter JD, et al. J Acquir Immune Defic Syndr 2008 48 1 26 34 10.1097/QAI.0b013e31816d9bf4 18360290 (Pubitemid 351600859)
28. HIV Drug Resistance Mutations by Drug Class, 2009 [ http://hivdb. stanford.edu/pages/download/resistanceMutations-handout.pdf ]
29. Bias, prevalence and kappa. Byrt T, Bishop J, Carlin JB, J Clin Epidemiol 1993 46 5 423 429 10.1016/0895-4356(93)90018-V 8501467 (Pubitemid 23194263)
30. The measurement of observer agreement for categorical data. Landis JR, Koch GG, Biometrics 1977 33 1 159 174 10.2307/2529310 843571 (Pubitemid 8054849)
31. Single Case Research, web based calculators for SCR analysis. (Version 1.0) College Station, TX: Texas A&M University [ http://www. singlecaseresearch.org/calculators/pabak-os ]
32. Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naive patients in Accra, Ghana. Sagoe KW, Dwidar M, Lartey M, Boamah I, Agyei AA, Hayford AA, Mingle JA, Arens MQ, J Clin Virol 2007 40 2 163 167 10.1016/j.jcv.2007.07.016 17827059 (Pubitemid 47419434)
33. Genotypic evaluation of etravirine sensitivity of clinical human immunodeficiency virus type 1 (HIV-1) isolates carrying resistance mutations to nevirapine and efavirenz. Oumar AA, Jnaoui K, Kabamba-Mukadi B, Yombi JC, Vandercam B, Goubau P, Ruelle J, Acta Clin Belg 2010 65 4 242 244 20954462
34. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine. Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S, Antimicrob Agents Chemother 2010 54 4 1596 1602 10.1128/AAC.01480-09 20124001
35. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. Parkin NT, Gupta S, Chappey C, Petropoulos CJ, Antimicrob Agents Chemother 2006 50 1 351 354 10.1128/AAC.50.1.351-354.2006 16377709 (Pubitemid 43042944)